Shanghai Pharmaceuticals Holding Co., Ltd (SHA:601607)
China
· Delayed Price · Currency is CNY 18.38
+0.02 (0.11%)
Apr 22, 2025, 1:45 PM CST
SHA:601607 Revenue
In the year 2024, Shanghai Pharmaceuticals Holding had annual revenue of 275.25B CNY with 5.75% growth. Shanghai Pharmaceuticals Holding had revenue of 65.62B in the quarter ending December 31, 2024, with 4.52% growth.
Revenue
275.25B
Revenue Growth
+5.75%
P/S Ratio
0.22
Revenue / Employee
5.57M
Employees
49,402
Market Cap
60.55B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 275.25B | 14.96B | 5.75% |
| Dec 31, 2023 | 260.30B | 28.31B | 12.21% |
| Dec 31, 2022 | 231.98B | 16.16B | 7.49% |
| Dec 31, 2021 | 215.82B | 23.92B | 12.46% |
| Dec 31, 2020 | 191.91B | 5.34B | 2.86% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Hengrui Medicine | 27.98B |
| Shenzhen Mindray Bio-Medical Electronics | 37.11B |
| WuXi AppTec | 37.92B |
| Zhangzhou Pientzehuang Pharmaceutical., | 10.91B |
| Aier Eye Hospital Group | 20.62B |
| Shanghai United Imaging Healthcare | 10.30B |
| Sichuan Biokin Pharmaceutical | 5.82B |
| Yunnan Baiyao Group Co.,Ltd | 40.03B |
Shanghai Pharmaceuticals Holding News
- 3 months ago - Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million - Benzinga
- 3 months ago - HUTCHMED to divest 45% stake in JV with Shanghai Pharma - Seeking Alpha